Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. J of Skin. 2021;5(1):s2. doi:10.25251/skin.5.supp.2